Condition
Pleural Mesothelioma|Metastatic Pleural Effusions
Estimated Enrollment: 18
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment
Study ID Numbers: 803776|P01CA066726
Study First Received: March 3, 2006
Last Updated: February 21, 2017
Estimated Primary Completion Date: April 2023
Primary Outcome Measures:
To determine toxicity of two doses of intrapleural BG00001 (Ad.hIFN-β over 8 days, and|To assess systemic and intrapleural cytokine responses as well as cellular and humoral immune responses after repeated BG00001 instillation,|and to assess, in a preliminary way, efficacy via tumor regression, time to progression and survival.
Sponsors and Collaborators:
University of Pennsylvania|National Cancer Institute (NCI)|Biogen
Website Link: https://ClinicalTrials.gov/show/NCT00299962
